Enlivex notifies availability of press release on FDA RMAT designation for Allocetra in knee osteoarthritis

• Enlivex press release posted on FDA RMAT designation for Allocetra in symptomatic age-related knee osteoarthritis for patients aged 64+.
• RMAT status may speed development via closer FDA engagement, accelerated approval pathways, priority review.
• Phase IIb randomized trial targets 182 patients in the US, EU; top-line data expected by end-Q2 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enlivex Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607130800PRIMZONEFULLFEED9761022) on July 13, 2026, and is solely responsible for the information contained therein.